Literature DB >> 26453649

Extensive brain demyelinating lesions under natalizumab: The role of anti-natalizumab antibodies.

Rabab Debs1, Elisabeth Maillart2, Robert Fahed2, Caroline Papeix2, Charles Duyckaerts2, Christine Stadelmann2, Damien Galanaud2, Catherine Lubetzki2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26453649     DOI： 10.1212/WNL.0000000000002084

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  3 in total

1.  Anti-natalizumab antibodies during 8 years of natalizumab treatment: effect on natalizumab concentration and α4-integrin receptor saturation.

Authors:  Zoé L E van Kempen; Johannis A van Rossum; Djoeke Doesburg; Iris Claessen; Annick de Vries; Anja Ten Brinke; Bob W van Oosten; Theo Rispens; Joep Killestein
Journal:  J Neurol       Date:  2019-04-19       Impact factor: 4.849

Review 2.  Immunopathology of Tumefactive Demyelinating Lesions-From Idiopathic to Drug-Related Cases.

Authors:  Aigli G Vakrakou; Maria-Evgenia Brinia; Ioanna Svolaki; Theodore Argyrakos; Leonidas Stefanis; Constantinos Kilidireas
Journal:  Front Neurol       Date:  2022-03-15       Impact factor: 4.003

3.  Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases.

Authors:  Aigli G Vakrakou; Dimitrios Tzanetakos; Maria-Eleptheria Evangelopoulos; Theodore Argyrakos; John S Tzartos; Maria Anagnostouli; Elissavet Andreadou; Georgios Koutsis; Georgios Velonakis; Panagiotis Toulas; Elias Gialafos; Antonios Dimitrakopoulos; Erasmia Psimenou; Leonidas Stefanis; Constantinos Kilidireas
Journal:  Ther Adv Neurol Disord       Date:  2021-05-18       Impact factor: 6.570
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.